Med-X, Inc. filed Amendment No. 4 to its Form S-1/A registration statement, covering the proposed resale of up to 16,248,842 post-split shares of common stock in connection with a planned direct listing on the Nasdaq Global Market.

Key Highlights

  • Shares registered: Up to 16,248,842 post-split shares of common stock are being registered for resale by existing stockholders identified in the prospectus.
  • Direct listing structure: The offering is structured as a direct listing, not a firm-commitment underwritten initial public offering; no investment bank is underwriting the resale on a firm-commitment basis.
  • No company proceeds: According to the filing, Med-X will not receive any proceeds from the sale of shares by the Registered Stockholders.
  • Capital raised to date: From inception on February 14, 2014, through October 14, 2026, the company raised an aggregate of approximately $38,081,204 in net proceeds from stock sales at an average post-split price of $2.89 per share.
  • Financial advisor: Maxim Group LLC has been engaged as financial advisor to assist with matters relating to the direct listing and will play a role in determining when shares are ready to trade on Nasdaq.
  • Emerging growth company: Med-X is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under applicable SEC definitions.

Med-X Pursues Nasdaq Direct Listing Via Registered Stockholder Resale

Med-X, Inc., a Nevada-incorporated company headquartered at 8236 Remmet Avenue, Canoga Park, California 91304, submitted Amendment No. 4 to its S-1/A registration statement under Registration No. 333-299158. The filing relates to a proposed direct listing on the Nasdaq Global Market, through which existing stockholders, identified in the prospectus as the "Registered Stockholders," may offer and sell up to 16,248,842 post-split shares of common stock. The company disclosed that the Registered Stockholders "may, or may not, elect to sell their shares of common stock covered by this prospectus, as and to the extent they may determine."

The filing states that no public market for Med-X common stock currently exists and that the shares have a limited history of trading in private transactions. The company has applied to list its common stock on the Nasdaq Global Market under the equity standard, which requires meeting minimum thresholds for stockholders' equity, public float, and shareholders. The filing notes that "there can be no assurance that its application will be approved." The company disclosed that recent private transaction prices "may have little or no relation to the opening public price" on Nasdaq or subsequent trading prices.

Under the direct listing process described in the filing, Nasdaq will accept pre-opening buy and sell orders on the day of initial listing, generating a "Current Reference Price" each second during a 10-minute "Display Only" period. Maxim Group LLC, in its capacity as financial advisor and also as a Registered Stockholder, must notify Nasdaq when shares are "ready to trade" and will approve proceeding at the Current Reference Price. The filing states the Advisor will base this determination "primarily on considerations of volume, timing and price." Matthew Mills is identified as Chief Executive Officer and agent for service of process.

What Was Disclosed

Med-X filed a fourth amendment to its S-1 registration statement to register up to 16,248,842 post-split shares for resale by existing stockholders in connection with a planned Nasdaq direct listing. The company will receive no proceeds from the resale and has engaged Maxim Group LLC as financial advisor.